An interventional study of Digital psychology intervention (ADOPT-CP) and Reminder Emails in Fibromyalgia and Chronic Pelvic Pain Syndrome, sponsored by Women's College Hospital. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Women's College Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Fibromyalgia with a site in Canada — 4 open to participants now, 4 under way, none of them phase 3. Fibromyalgia · Canada.
Among the 42 studies in Fibromyalgia with a site in Canada, this one is the 20th largest by planned enrollment of the 37 interventional ones that give a count, is the only one that started in 2027, is one of 16 with no phase, and was the 42nd registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →4 of the 42 studies in Fibromyalgia with a site in Canada are open now. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–75 · Healthy volunteers
Wilderman Medical Clinic · Sites in Canada
Ages 18+
BC Women's Hospital & Health Centre · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 67 across the 37 interventional studies, 81 across the 5 observational. Of the 36 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 42 have an industry lead sponsor. The 10 most frequent:
Women's College Hospital is the lead sponsor of 87 studies on the registry; 16 are open to participants now.
Women's College Hospital has 2 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
2 of the studies in Fibromyalgia with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03910010Nova Scotia Health AuthorityBrain Imaging Study on Biomarkers for Fibromyalgia | 2027-02 |
| NCT07659873Women's College HospitalAdvancing Online Psychology Tools for Chronic Pain | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 42 studies in Fibromyalgia with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Chronic pain affects more than 20% of Canadians and is associated with significant impacts on physical function, mental health, and quality of life. Despite efforts to improve access to multidisciplinary pain care through centralized referral systems, many patients continue to experience prolonged wait times before receiving treatment.
This study evaluates a self-guided digital psychological intervention designed to support chronic pain self-management during the waiting period for specialized pain care. The intervention was developed through a collaboration between the Transitional Pain Service and ManagingLife and aims to improve access to evidence-based psychological support, enhance self-management skills, and reduce pain-related distress among individuals living with chronic pain.
The Advancing Online Psychology Tools for Chronic Pain (ADOPT-CP) intervention provides participants with access to the Manage My Pain (MMP) platform, including a self-guided Acceptance and Commitment Therapy (ACT)-based digital psychology program and Solace, an artificial intelligence (AI)-enabled conversational support tool for chronic pain. Together, these tools are designed to support pain self-management, emotional coping, and engagement in care.
This study will evaluate the feasibility, acceptability, and preliminary clinical effects of the ADOPT-CP intervention among individuals waiting to access multidisciplinary chronic pain services through the Toronto Academic Pain Medicine Institute (TAPMI). The intervention aims to provide accessible psychological support and self-management resources during the waiting period for specialized pain care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The ADOPT-CP intervention includes the Manage My Pain (MMP) app with integrated tools: a customizable pain tracker for monitoring symptoms and generating reports, the Pain Guide with educational content on pain management, a self-guided Acceptance and Commitment Therapy (ACT)-based psychology program, and Solace, an AI-driven conversational agent designed to provide structured, evidence-based psychological support for chronic pain self-management.
Other: Digital psychology intervention (ADOPT-CP)
The control group will receive treatment as usual plus weekly emailed resources. These resources include materials introduced during the TAPMI orientation session, including Power Over Pain and Progress Over Pain.
Other: Reminder Emails
The intervention, Manage My Pain (MMP), is a clinically validated app-based platform that supports individuals with chronic pain in self-managing their symptoms and improving communication and engagement with their care team.
Weekly emailed pain self-management resources introduced during the Toronto Academic Pain Medicine Institute (TAPMI) orientation
Trial feasibility
Measured according to the CONSORT criteria and include: eligibility rate, recruitment rate, retention rate, measure completion, absence of or minor adverse events.
Time frame: 10 weeks
Engagement with the digital ADOPT-CP intervention
Measured via MMP app analytics (usage rates, completion of psychology program, etc.)
Time frame: 10 weeks
Acceptability and Appropriateness of the ADOPT-CP intervention
The Treatment Evaluation Inventory-Short Form (TEI-SF) is a self-report measure assessing the acceptability and perceived appropriateness of a treatment or intervention, with higher scores indicating greater treatment acceptability.
Time frame: 10 weeks
Acceptability and Adherence of the ADOPT-CP intervention
The Treatment Acceptability/Adherence Scale (TAAS) is a self-report measure assessing perceived acceptability of an intervention and anticipated or actual adherence, with higher scores indicating greater acceptability and adherence.
Time frame: 10 weeks
Experience using the ADOPT-CP intervention
a semi-structured interview guide will be used to explore participant experiences, barriers and facilitators to use, acceptability, engagement, and opportunities to refine the digital intervention prior to a larger trial.
Time frame: 14 weeks
Quality of Life and Pain Interference
Modified PROMIS-29 Health Domains (Quality of Life and Pain Interference 8a): A validated patient-reported outcome system assessing the impact of health conditions on physical, mental, and social functioning. Higher scores indicate greater pain interference and worse health-related quality of life, while lower scores indicate better functioning and quality of life.
Time frame: 10 weeks
Pain Acceptance
Measured by the Chronic Pain Acceptance Questionnaire-Short Form: A validated self-report measure of acceptance of chronic pain. Higher scores indicate greater acceptance of chronic pain, including continued activity engagement and reduced avoidance of pain-related experiences.
Time frame: 10 weeks
Psychological Flexibility
Measured by the Acceptance and Action Questionnaire-II (AAQ-II): A validated self-report measure of psychological inflexibility and experiential avoidance. Higher scores indicate greater psychological inflexibility and experiential avoidance, while lower scores indicate greater psychological flexibility.
Time frame: 10 weeks
Kinesiophobia
Measured by the Tampa Scale of Kinesiophobia (TSK): a validated self-report questionnaire used to assess fear of movement and fear of re-injury. Higher scores indicate greater fear of movement.
Time frame: 10 weeks
Pain Resiliency
Measured by the Pain Resiliency Scale: Measures how well a person can adapt and maintain function despite chronic pain. Higher scores indicate greater resilience in coping with chronic pain, while lower scores indicate reduced adaptive coping.
Time frame: 10 weeks
Plan to share: No — At this time, no external data sharing arrangements or future secondary use arrangements are planned. Study data will be retained and used only for the purposes described in this protocol. If future secondary use or collaboration with internal or external investigators is proposed at a later date, this would occur only in accordance with participant consent, WCH REB requirements, and any required data sharing agreements or institutional approvals. Results from this study may be disseminated through academic publications, presentations, and reports. Only aggregate or de-identified information will be used for these purposes. No participant-identifiable information will be included in any publication or dissemination arising from this study. Study data will not be shared with individuals outside the research team for secondary use.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Oct 2027, 9 months later.
Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 9 months is below that.
Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Women's College Hospital